tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jonathan Chang, 74 are a BUY (63.79%), 42 are a HOLD (36.21%).
Analyst Jonathan Chang, currently employed carries an average stock price target met ratio of 54.12% that have a potential upside of 45.9% achieved within 293 days. Previously, Jonathan Chang worked at LEERINK.
Jonathan Chang’s has documented 197 price targets and ratings displayed on 19 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on KPTI, Karyopharm Therapeutics at 10-Jan-2023.
Analyst best performing recommendations are on IMGN (IMMUNOGEN).
The best stock recommendation documented was for IMGN (IMMUNOGEN) at 11/30/2021. The price target of $7 was fulfilled within 2 days with a profit of $0.83 (13.45%) receiving and performance score of 67.26.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Sell
$1
$-0.01 (-0.99%)
$4
1 years 3 months 7 days ago
(10-Aug-2023)
3/4 (75%)
$0.18 (21.95%)
245
Buy
$5
$3.99 (395.05%)
1 years 10 months 14 days ago
(03-Jan-2023)
0/2 (0%)
$3.33 (199.40%)
Buy
$9
$8.22 (1053.85%)
$9
2 years 9 days ago
(09-Nov-2022)
2/3 (66.67%)
$1.29 (98.13%)
340
Hold
$3
$1.99 (197.03%)
2 years 6 months 8 days ago
(09-May-2022)
1/5 (20%)
$1.46 (94.81%)
377
Buy
$6
$5.22 (669.23%)
$16
5 years 6 months 11 days ago
(07-May-2019)
1/3 (33.33%)
$6.36 (92.59%)
388
What Year was the first public recommendation made by Jonathan Chang?
